PHASE-II TRIAL OF LYMPHOBLASTOID INTERFERON IN METASTATIC MALIGNANT-MELANOMA

  • 1 January 1985
    • journal article
    • research article
    • Vol. 69  (7-8) , 813-816
Abstract
Thirty-three patients with metastatic malignant melanoma, some of whom had received previous chemotherapy, immunotherapy, or radiotherapy, were entered in a trial of 3 different doses and schedules of administration of lymphoblastoid .alpha. interferon. The overall response rate was 9%; some patients had long-lasting response and 2 achieved complete response. There was no clear advantage to any 1 regimen. Dose-related flu-like syndrome, granulocytopenia, hepatocellular enzyme elevation and anemia were observed as the most common toxic effects. Interferon deserves further study in the treatment of malignant melanoma.